LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Pipeline Expansion Kallyope's advanced pipeline focusing on novel neural circuits and its late-stage lead products for migraine and metabolic disorders present significant sales opportunities with healthcare providers seeking breakthrough therapies in neurology and metabolic health.

Strategic Partnerships & Funding The company's recent $8.2 million grant from the Bill & Melinda Gates Foundation and its collaborations, such as the GPCR target project, indicate potential for forming strategic alliances and expanding outreach within global health and biotech markets.

Public Market Entrance As Kallyope explores an initial public offering, there is an opportunity to engage investors and partners interested in innovative biotech solutions for obesity and metabolic diseases, opening avenues for future collaborations and funding.

Focus on Neurological Therapies With upcoming presentations at major neurology conferences and a focus on acute migraine treatments, sales teams can target neurologists, pain management clinics, and healthcare institutions actively seeking new migraine therapies.

Technical & Data Capabilities Kallyope’s utilization of advanced technologies like the Klarity Platform and its focus on neural signaling integration suggest opportunities for collaborative R&D, licensing deals, or technology services with other biotech and pharmaceutical firms.

Kallyope Tech Stack

Kallyope uses 8 technology products and services including Open Graph, git, Microsoft Excel, and more. Explore Kallyope's tech stack below.

  • Open Graph
    Content Management System
  • git
    Development
  • Microsoft Excel
    Editors
  • Python
    Programming Languages
  • Java
    Programming Languages
  • Paylocity
    Recruitment Marketing
  • HSTS
    Security
  • Google Tag Manager
    Tag Management

Media & News

Kallyope's Email Address Formats

Kallyope uses at least 1 format(s):
Kallyope Email FormatsExamplePercentage
First@kallyope.comJohn@kallyope.com
33%
First.Last@kallyope.comJohn.Doe@kallyope.com
17%
First@kallyope.comJohn@kallyope.com
33%
First.Last@kallyope.comJohn.Doe@kallyope.com
17%

Frequently Asked Questions

Where is Kallyope's headquarters located?

Minus sign iconPlus sign iconKallyope's main headquarters is located at 430 East 29th Street New York, New York 10016 United States. The company has employees across 3 continents, including North AmericaAsiaSouth America.

What is Kallyope's phone number?

Minus sign iconPlus sign icon You can contact Kallyope's main corporate office by phone at
+1-312-961-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Kallyope's official website and social media links?

Minus sign iconPlus sign iconKallyope's official website is kallyope.com and has social profiles on LinkedInCrunchbase.

What is Kallyope's SIC code NAICS code?

Minus sign iconPlus sign iconKallyope's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Kallyope have currently?

Minus sign iconPlus sign iconAs of March 2026, Kallyope has approximately 66 employees across 3 continents, including North AmericaAsiaSouth America. Key team members include Chief Scientific Officer: S. P.Chief Financial Officer: P. E. F.Chief Medical Officer: B. L.. Explore Kallyope's employee directory with LeadIQ.

What industry does Kallyope belong to?

Minus sign iconPlus sign iconKallyope operates in the Biotechnology Research industry.

What technology does Kallyope use?

Minus sign iconPlus sign iconKallyope's tech stack includes Open GraphgitMicrosoft ExcelPythonJavaPaylocityHSTSGoogle Tag Manager.

What is Kallyope's email format?

Minus sign iconPlus sign iconKallyope's email format typically follows the pattern of First@kallyope.com. Find more Kallyope email formats with LeadIQ.

How much funding has Kallyope raised to date?

Minus sign iconPlus sign icon As of March 2026, Kallyope has raised $1.2B in funding. The last funding round occurred on Feb 15, 2022 for $236M.

When was Kallyope founded?

Minus sign iconPlus sign iconKallyope was founded in 2015.

Kallyope

Biotechnology ResearchNew York, United States51-200 Employees

At Kallyope, we are leveraging unique insights into neural signaling pathways and developing innovative medicines for the treatment of migraine and metabolic disorders. Our late-stage pipeline focuses on delivering effective, easy to use, and well-tolerated agents based on novel neural circuits. 

Kallyope was founded by world-leading neuroscientists whose groundbreaking research into previously unexplored neural networks is now being carried forward by a team of experienced drug developers. Based in New York City, our accomplished scientists and drug developers bring together agile innovation and real-world focus to create major value for patients. 

Our pipeline is enabled by the Klarity™ Platform, including our lead migraine candidate moving into pivotal studies for the acute treatment of migraine, and our novel metabolism programs based on a novel feeding circuit set to enter clinical studies in mid-2026.

Section iconCompany Overview

Headquarters
430 East 29th Street New York, New York 10016 United States
Phone number
+1-312-961-****
Website
kallyope.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $1.2B

    Kallyope has raised a total of $1.2B of funding over 8 rounds. Their latest funding round was raised on Feb 15, 2022 in the amount of $236Mas a Series D.

  • $25M$50M

    Kallyope's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $1.2B

    Kallyope has raised a total of $1.2B of funding over 8 rounds. Their latest funding round was raised on Feb 15, 2022 in the amount of $236Mas a Series D.

  • $25M$50M

    Kallyope's revenue is estimated to be in the range of $25M$50M

Company Leadership

  • Stylized image of a person
    S. P.
    Chief Scientific Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    P. E. F.
    Chief Financial Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    B. L.
    Chief Medical Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. G.
    President & Chief Executive Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. B.
    Head Of Information Technology
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    A. W.
    Senior Vp - Research & Development
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. B.
    Head Of Information Technology
    Phone icon
    Mobile Phone
  • Stylized image of a person
    I. S.
    Senior Vice President, Preclinical Development
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. A.
    Sr. Director, Head Of Data Management
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. L.
    Vp, Head Of Biometrics
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.